பம்ப் பயன்பாடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article
Share this article
ResearchAndMarkets.com s offering.
The therapeutic market for T1D within the 8MM will grow from $4.9B in 2019 at a significant compound annual growth rate (CAGR) of 17.2% to $24B by 2029.
In particular, the publisher expects the US market will contribute the most to the T1D market s growth, contributing $4.3B sales in 2019 (87.7% of the T1D market) and $20.3B in 2029 (84.7% of the T1D market).
The launch of the first disease-modifying therapeutics will be the main drivers of growth over the forecast period, with the first preventative therapeutic for T1D, Teplizumab, expected to launch in the US during the forecast period. Other major drivers for the T1D market include the increased T1D diagnosed prevalence, and the uptake of novel ultra-rapid-acting and ultra-long-acting insulin analogs. ....

United Kingdom , Laura Wood , E St Office Hours Call , Mannkind Corporation , Lexicon Pharmaceuticals Portfolio Assessment , Office Hours Call , Diasome Pharmaceuticals Portfolio Assessment , Drug Forecast , Market Analysis , Annual Growth Rate , Opinion Leaders , Topics Covered , Market Will Grow , Veteran Players Use Various Strategies , Defend Insulin Franchises , Biosimilar Erosion , While New Players Invest , Future Therapies Leave Significant Unmet Needs , Pump Usage , Increased Market Entry , Beta Cell Regenerative , Islet Autoreactivity , Modifying Therapies , Managing Glycemic , Weight Management , Associated Metabolic ,